CRISPR Therapeutics AG (CRSP) Cash from Operations (2015 - 2026)

CRISPR Therapeutics AG has disclosed Cash from Operations across 12 years of filings, most recently posting 108897000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 108897000.0, down 101.86% year-over-year; the trailing twelve-month figure through Mar 2026 was 399964000.0 (down 30.51% YoY), and the FY2025 annual result was 345014000.0, down 141.65% from the prior year.
• Cash from Operations came in at 108897000.0 for Q1 2026 at CRISPR Therapeutics AG, down from 92553000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 109752000.0 in Q1 2024 to a low of 141956000.0 in Q2 2022.
• The 5-year median for Cash from Operations is 96073000.0 (2023), against an average of 79576529.41.
• Peak annual rise in Cash from Operations reached 1147.32% in 2024, while the deepest fall reached 168.25% in 2024.
• CRISPR Therapeutics AG's Cash from Operations stood at 113328000.0 in 2022, then advanced by 15.23% to 96073000.0 in 2023, then jumped by 47.92% to 50031000.0 in 2024, then sank by 84.99% to 92553000.0 in 2025, then fell by 17.66% to 108897000.0 in 2026.
• The last three Cash from Operations figures came in at 108897000.0 (Q1 2026), 92553000.0 (Q4 2025), and 84634000.0 (Q3 2025), per Business Quant data.